Terms: = Lung cancer AND ERBB4, MGC138404, 2066, ENSG00000178568, Q15303, p180erbB4, HER4 AND Clinical Outcome
4 results:
1. Genetic landscape of patients with ALK-rearranged non-small-cell lung cancer (NSCLC) and response to ceritinib in ASCEND-1 study.
Tan DS; Thomas M; Kim DW; Szpakowski S; Urban P; Mehra R; Chow LQM; Sharma S; Solomon BJ; Felip E; Camidge DR; Vansteenkiste J; Petruzzelli L; Pantano S; Shaw AT
Lung Cancer; 2022 Jan; 163():7-13. PubMed ID: 34890832
[TBL] [Abstract] [Full Text] [Related]
2. Co-expression of receptors of the HER family correlates with clinical outcome in non-small cell lung cancer (NSCLC).
Bellezza G; Del Sordo R; Colella R; Ludovini V; Ragusa M; Bianconi F; Ferri I; Borri F; Chiari R; Puma F; Crinò L; Sidoni A
Virchows Arch; 2013 Nov; 463(5):663-71. PubMed ID: 24013863
[TBL] [Abstract] [Full Text] [Related]
3. Correlated expression of erbB-3 with hormone receptor expression and favorable clinical outcome in invasive ductal carcinomas of the breast.
Lee Y; Cho S; Seo JH; Shin BK; Kim HK; Kim I; Kim A
Am J Clin Pathol; 2007 Dec; 128(6):1041-9. PubMed ID: 18024331
[TBL] [Abstract] [Full Text] [Related]
4. Epidermal growth factor receptor inhibitors: a new prospective in the treatment of lung cancer.
Tiseo M; Loprevite M; Ardizzoni A
Curr Med Chem Anticancer Agents; 2004 Mar; 4(2):139-48. PubMed ID: 15032719
[TBL] [Abstract] [Full Text] [Related]
